Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies

• John N. Allan,
• Javier Pinilla-Ibarz,
• Douglas E. Gladstone,
• Krish Patel,
• Jeff P. Sharman,
• William G. Wierda,
• Michael Y. Choi,
• Susan M. O’Brien,
• Mazyar Shadman,
• Matthew S. Davids,
• John M. Pagel,
• Habte A. Yimer,
• Renee Ward,
• Gary Acton,
• Pietro Taverna,
• Daniel L. Combs,
• Judith A. Fox,
• Richard R. Furman,
• Jennifer R. Brown

Affiliations

John N. Allan

Weill Cornell Medicine, Department of Medicine, New York

Javier Pinilla-Ibarz

Moffitt Cancer Center, Tampa, FL

Douglas E. Gladstone

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

Krish Patel

Swedish Cancer Institute, Seattle, WA

Jeff P. Sharman

Willamette Valley Cancer Institute/US Oncology, Eugene, OR

William G. Wierda

MD Anderson Cancer Center, Houston, TX

Michael Y. Choi

Moores Cancer Center, University of California San Diego, La Jolla, CA

Susan M. O’Brien

Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA

Mazyar Shadman

Fred Hutchinson Cancer Research Center, Seattle, WA

Matthew S. Davids

CLL Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

John M. Pagel

Swedish Cancer Institute, Seattle, WA

Habte A. Yimer

Texas Oncology/US Oncology Research, Tyler, TX

Renee Ward

Sunesis Pharmaceuticals, South San Francisco, CA

Gary Acton

Sunesis Pharmaceuticals, South San Francisco, CA

Pietro Taverna

Sunesis Pharmaceuticals, South San Francisco, CA

Daniel L. Combs

Combs Consulting Service, Mountain View, CA

Judith A. Fox

Sunesis Pharmaceuticals, South San Francisco, CA

Richard R. Furman

Weill Cornell Medicine, Department of Medicine, New York

Jennifer R. Brown

CLL Center, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA